An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments
Overview
- Phase
- Not Applicable
- Intervention
- Prostaglandin Analogue -Containing IOP-Lowering Therapy
- Conditions
- Glaucoma, Open-Angle
- Sponsor
- Allergan
- Enrollment
- 358
- Primary Endpoint
- Change From Baseline in Intraocular Pressure (IOP) in the Left Eye
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
This study is a prospective, observational study of changing from any IOP-lowering treatment to a prostaglandin analogue-containing IOP-lowering medication for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT). The decision to change medications lies with the physician according to their standard practice.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of primary open angle glaucoma (POAG) or ocular hypertension (OHT)
- •Previously prescribed any IOP-lowering therapy which has been stopped and a new prostaglandin analogue -containing IOP-lowering therapy started
Exclusion Criteria
- Not provided
Arms & Interventions
Patients with POAG or OHT
Patients with POAG or OHT on current IOP-lowering therapy who are prescribed a prostaglandin analogue -containing IOP-lowering therapy by the physician. The decision to prescribe a change in IOP-lowering therapy lies with the physician according to their standard practice.
Intervention: Prostaglandin Analogue -Containing IOP-Lowering Therapy
Outcomes
Primary Outcomes
Change From Baseline in Intraocular Pressure (IOP) in the Left Eye
Time Frame: Baseline, Week 12
IOP is a measurement of the fluid pressure inside the eye. A negative change from Baseline indicates an improvement.
Change From Baseline in Intraocular Pressure (IOP) in the Right Eye
Time Frame: Baseline, Week 12
IOP is a measurement of the fluid pressure inside the eye. A negative change from Baseline indicates an improvement.
Secondary Outcomes
- Patient Assessment of Overall Tolerability With New Treatment Using a 4-Point Scale(12 Weeks)
- Physician Assessment of Tolerability With New Treatment Using a 4-Point Scale(12 Weeks)
- Percentage of Participants Who Discontinue the Use of New Treatment Prior to 12 Weeks(12 Weeks)
- Percentage of Participants Who Continue the New Treatment After 12 Weeks(12 Weeks)
- Physician Assessment of Adherence to New Treatment Using a 4-Point Scale(12 Weeks)
- Percentage of Participants Reaching Individual IOP Target After 12 Weeks(12 Weeks)
- Physician Assessment of Efficacy Using a 5-Point Scale(12 Weeks)